Detection rates for abnormal cervical smears: what are we screening for?

We analysed rates of detection for smear abnormalities in 255,000 women served by the Bristol screening programme. The programme began in 1966 with the aim of eradicating the 30-40 deaths each year in Bristol from cervical cancer. Organisation has been good and population uptake has been high for the past 15 years. Records were computerised in 1977. During the 1988 to 1993 screening round, 225,974 women were tested. New smear abnormalities were found in 15,551, of whom nearly 6000 were referred for colposcopy. These numbers are excessively high in comparison with the incidence of the malignancy we are trying to prevent. The effect of screening on death rates in Bristol is too small to detect. Our conclusion is that despite good organisation of the service, much of our effort in Bristol is devoted to limiting the harm done to healthy women and to protecting our staff from litigation as cases of serious disease continue to occur. The real lesson from 30 years' cervical screening is that no matter how obvious the predicted benefit may seem for any screening test, introduction should never take place without adequate prior evaluation of both positive and negative effects in controlled trials.

[1]  W. Creasman,et al.  Carcinoma In Situ of the Cervix An Analysis of 861 Patients , 1972, Obstetrics and gynecology.

[2]  J. Macgregor,et al.  MORTALITY FROM CARCINOMA OF CERVIX UTERI IN BRITAIN , 1978, The Lancet.

[3]  A. Adelstein,et al.  Mortality from carcinoma of the uterus. An international cohort study. , 1971, British journal of preventive & social medicine.

[4]  A. Sincock,et al.  Quantitative determination of acid‐labile dna in cervical intraepithelial neoplasia , 1991, Cancer.

[5]  D. Evans,et al.  Terminology in gynaecological cytopathology: report of the Working Party of The British Society for Clinical Cytology , 1986, Journal of clinical pathology.

[6]  P. Sasieni Trends in cervical cancer mortality , 1991, The Lancet.

[7]  P. Kolstad,et al.  Long-Term Followup of 1121 Cases of Carcinoma In Situ , 1976, Obstetrics and gynecology.

[8]  J. Cuzick,et al.  Human papillomavirus type 16 DNA in cervical smears as predictor of high-grade cervical cancer , 1992, The Lancet.

[9]  S. Adalsteinsson,et al.  Trends in cervical and breast cancer in Iceland. A statistical evaluation of trends in incidence and mortality for the period 1955–1989, their relation to screening and prediction to the year 2000 , 1991, International journal of cancer.

[10]  J. Macgregor,et al.  Screening for cervical intraepithelial neoplasia in north east Scotland shows fall in incidence and mortality from invasive cancer with concomitant rise in preinvasive disease , 1994, BMJ.

[11]  H. Kitchener,et al.  Management of women with mild and moderate cervical dyskaryosis , 1994, BMJ.

[12]  J. Thornton,et al.  Screening for cervical cancer Graphs may mislead , 1994, BMJ.

[13]  Jones Rw,et al.  The invasive potential of carcinoma in situ of the cervix. , 1984 .